GSK's Jemperli meets main goal in mid-stage rectal cancer trial

GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for this cancer can lead to significant lifelong side effects. Jemperli's safety profile remains consistent with prior studies in solid tumors. GSK anticipates Jemperli will significantly contribute to its long-term sales targets.

Raccontata daeconomictimes.indiatimes.combenzinga.comfiercepharma.com